20 results
Thumbnail

D2.475 - Treatment delay and likelihood of remission on omalizumab in chronic spontaneous urticaria: a real-world observational study

Thumbnail

D2.465 - Omalizumab Enhances Safety and Supports Completion of Oral Immunotherapy in High-Risk Patients

Thumbnail

D2.466 - More options for the treatment of Chronic Spontaneous Urticaria: Tezepelumab

Thumbnail

D2.467 - Management of Netherton syndrome and hereditary angioedema with concurrent biologic therapy: a novel case

Thumbnail

D2.468 - Real-world effectiveness and safety of dupilumab in pediatric atopic dermatitis: a retrospective cohort study

Thumbnail

D2.469 - Pre-switch perceptions of omalizumab biosimilar prefilled pen in pediatric allergy: a cross-sectional survey

Thumbnail

D2.472 - Immunology Innovation Program: Developing Antibodies Against Novel Targets Through Co-creation

Thumbnail

D2.474 - Use of Dupilumab as treatment for Eosinophilic Enteritis: a case report

Thumbnail

D2.476 - Mepolizumab Enables Meaningful Real-World Improvements in SNOT-22 and Smell Dysfunction in Chronic Rhinosinusitis with Nasal Polyps: Post Hoc Analysis of REALITI-N at 3 and 6 Months

Thumbnail

D3.181 - Oral Immunotherapy for food allergy through a personalised approach

Thumbnail

D3.182 - Initiating Sublingual Immunotherapy in Pre-Adolescence (

Thumbnail

D3.193 - Dual Blockade of TSLP and IL11 with a bispecific antibody: A Promising Strategy for the Treatment of Asthma and Other Airway Disorders

Thumbnail

D3.194 - Carry-Over Effect of House Dust Mite (HDM) Immunotherapy for Allergic Respiratory Conditions in Pediatric and Adolescent Populations: A Systematic Review and Narrative Synthesis

Thumbnail

D3.189 - Oral Immunotherapy–Associated Eosinophilic Esophagitis: A Pediatric Case Report

Thumbnail

D3.183 - Determination of IgE antibodies against recombinant allergens (Phl p 1 and Phl p 5) in a random sample of patients from Madrid with pollinosis before and after one year of subcutaneous immunotherapy

Thumbnail

D3.187 - Sustained Clinical Benefit of Allergen Immunotherapy in Allergic Rhinitis: A Real-Life Study

Thumbnail

D3.188 - Real-Life Effectiveness of Subcutaneous Allergen Immunotherapy Assessed by Medication Consumption: A Retrospective Cohort Study

Thumbnail

D3.190 - Protocol for a real-world Study to Track Response to Oralair in Naïve patients with Grass pollen allergy (STRONG) in the Netherlands

Thumbnail

D3.191 - Demonstrating the Stability of Allergoids, the Next Generation of Allergen Therapy

Thumbnail

D3.192 - Safety of AIT with Depigmented-polymerized extracts in patients with severe allergic asthma. A subanalysis of the SAGITAL study